Bradford Crutchfield - Feb 15, 2022 Form 4 Insider Report for 10x Genomics, Inc. (TXG)

Role
Chief Commercial Officer
Signature
/s/ Eric S. Whitaker, as Attorney-in-Fact
Stock symbol
TXG
Transactions as of
Feb 15, 2022
Transactions value $
-$1,597,541
Form type
4
Date filed
2/17/2022, 03:48 PM
Previous filing
Jan 14, 2022
Next filing
Feb 24, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction TXG Class A Common Stock Options Exercise $19.7K +17K +17.41% $1.16 115K Feb 15, 2022 Direct F1
transaction TXG Class A Common Stock Sale -$1.62M -17K -14.83% $95.13 97.7K Feb 15, 2022 Direct F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction TXG Stock Option (right to buy) Options Exercise $0 -17K -4.16% $0.00 392K Feb 15, 2022 Class A Common Stock 17K $1.16 Direct F1, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The transactions reported herein were effected pursuant to the Reporting Person's Rule 10b5-1 trading plan.
F2 This transaction was executed in multiple trades at prices ranging from $95.00 to $95.38. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
F3 This option, originally for 800,000 shares, of which 408,000 shares have been exercised, vested as to one-fourth of the shares on February 2, 2018 and one forty-eighth of the shares subject to the option vest each month thereafter, subject to the Reporting Person continuing as a service provider through each such date.